Although a variety of checkpoint inhibitors targeting CLTA-4, PD-1 and PD-L1 have shown impressive potent anti-tumor immunity and durable responses in some patients, there is still a large percentage of patients who do not respond to and therefore cannot benefit from these treatments [37], emphasizing the importance of finding novel immune checkpoint targets or combinational strategies. The gene discussed is CD274; the disease is neoplasm.